Eye Disease News and Research

RSS

Eye diseases are widespread around the globe. According to the World Health Organization, the most important three eye diseases or conditions that are a potential threat to the global population are diabetic retinopathy, glaucoma, and age-related macular degeneration. One more vital reason for visual harm is refractive errors. Some of the important reasons for vision loss or low vision are age, healthcare, gender, genetic problems and the prevalence of family history.

Report: 235 new medicines in development to treat diabetes

A record 235 new medicines to treat diabetes, one of the fastest-growing diseases in America, are being developed by America's pharmaceutical research and biotechnology companies, according to a national report unveiled today in Charleston.

26 May 2010

Significant progress on international development strategy for stem cell-derived human corneal tissue

International Stem Cell Corporation, www.intlstemcell.com, today announced significant progress on its international development strategy for stem cell-derived human corneal tissue. Such tissue can potentially be used to replace cadaver-derived corneas in treatment of severe corneal vision impairment and to eliminate the need to use live animals in safety testing of drugs, chemicals and consumer products.

25 May 2010

Computerized systems can detect early eye problems related to diabetes: UI team

People with diabetes have an increased risk of blindness, yet nearly half of the approximately 23 million Americans with diabetes do not get an annual eye exam to detect possible problems.

13 May 2010

pSivida reports consolidated net loss of $2.7 million for third-quarter 2010

pSivida Corp., a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its third quarter and nine months ended March 31, 2010.

13 May 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.

12 May 2010

NEI renews K12 grant for Mass. Eye and Ear to fund Harvard Vision Clinical Scientist Development Program

The Massachusetts Eye and Ear Infirmary, Harvard Medical School Department of Ophthalmology, has been awarded a grant renewal from the National Institutes of Health, National Eye Institute (NEI), to recruit, train and support first-rate clinician scientists to promote translational and clinical research into cures for eye disease.

11 May 2010

Telemedical Retinal Image Analysis and Diagnosis technology permits early detection of diabetic retinopathy

Automated Medical Diagnostics, a startup company based in Memphis, envisions its product helping to preserve the sight of millions of people at risk of vision loss from diabetic retinopathy.

7 May 2010

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

The Burnier International Ocular Pathology Society is holding a Scientific Colloquium in Montreal today to mark the tenth anniversary of the McGill University Health Centre's Henry C. Witelson Ocular Pathology Laboratory. The lab is an internationally reputed centre for the study and treatment of eye diseases and is leading a global network for the sharing of healthcare knowledge and expertise.

7 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

TearScience completes $44.5 million Series C funding

TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. The company's existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures completed the round. The funding will allow TearScience to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.

5 May 2010

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Scientists have shown that through eye examinations, doctors can identify infants who are most likely to benefit from early treatment for a potentially blinding eye condition called retinopathy of prematurity, resulting in better vision for many children.

4 May 2010

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that Ryo Kubota, M.D., Ph.D., Acucela's chairman, president and chief executive officer, has been invited to participate in Retina International's annual Scientific & Medical Advisory Board meeting being held in Fort Lauderdale, Florida on May 3, 2010.

3 May 2010

Protect eyes from sun's UV rays to decrease risk of eye diseases, disorders

With summer right around the corner, more people will be spending time outdoors and UV protection will be top of mind. Unfortunately, most people think about the protection of their skin, when they should also be considering the safety of their eyes. In fact, according to the American Optometric Association's (AOA) American Eye-Q® survey, only one-third of Americans said UV protection is the most important factor they consider when purchasing sunglasses.

3 May 2010

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease, and cataracts than non-Hispanic whites, researchers found. These are the first estimates of visual impairment and eye disease development in Latinos, the largest and fastest growing minority population in the United States.

3 May 2010

IRIDEX commences commercial shipment of IQ 532 laser systems

IRIDEX Corporation, today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.

30 Apr 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

ISTA Pharmaceuticals, Inc., today reported financial results for the quarter ended March 31, 2010. First quarter 2010 net revenues were $28.3 million, an increase of 39% from the first quarter of 2009. Net income for the first quarter ended March 31, 2010, was $0.5 million, or $0.01 per share, compared to a net loss of $19.6 million, or $0.59 per share, for the first quarter ended March 31, 2009.

30 Apr 2010

pSivida announces presentations on bioerodible technologies for degenerative eye disease

pSivida Corp., a leader in the development of back of the eye drug delivery systems, today announced that two poster presentations will be made at the upcoming ARVO meeting on one of pSivida's next generation bioerodible technologies for degenerative eye disease. It marks a key step toward the ability to use pSivida's bioerodible technologies to develop treatments for glaucoma and other degenerative eye diseases, diseases that affect millions of Americans.

30 Apr 2010

New tool to detect inflammatory eye disease at molecular level before damage occurs

Forget what you know about how diseases are diagnosed-new research published in the May 2010 print issue of The FASEB Journal details a noninvasive ground-breaking tool that detects signs of disease at early molecular stages before symptoms can be seen using traditional methods.

30 Apr 2010

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).

26 Apr 2010

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

Advanced Cell Technology, Inc. announced today that it has completed key animal studies in connection with its Phase I multicenter study using embryonic stem cell derived Retinal Pigment Epithelium (RPE) cells to treat patients with Stargardt's Macular Dystrophy (SMD), for which it filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) in November. The studies demonstrated an excellent safety profile with no safety signals such as tumors or ectopic tissues.

24 Apr 2010

Eye Disease News and Research

Further Reading

Report: 235 new medicines in development to treat diabetes

Significant progress on international development strategy for stem cell-derived human corneal tissue

Computerized systems can detect early eye problems related to diabetes: UI team

pSivida reports consolidated net loss of $2.7 million for third-quarter 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

NEI renews K12 grant for Mass. Eye and Ear to fund Harvard Vision Clinical Scientist Development Program

Telemedical Retinal Image Analysis and Diagnosis technology permits early detection of diabetic retinopathy

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

TearScience completes $44.5 million Series C funding

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Protect eyes from sun's UV rays to decrease risk of eye diseases, disorders

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

IRIDEX commences commercial shipment of IQ 532 laser systems

ISTA Pharmaceuticals first-quarter net revenues up 39%

pSivida announces presentations on bioerodible technologies for degenerative eye disease

New tool to detect inflammatory eye disease at molecular level before damage occurs

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News